Compare Stocks: ADVM, RCKT, LXEO, and IPSC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$4.36	$4.30	$1.78 ▼ $5.75	$96.26M	0.87	452,470 shs	N/A
IPSC Century Therapeutics	$1.92 -0.5%	$2.19	$0.44 ▼ $3.04	$348.08M	1.57	656,371 shs	489,279 shs
LXEO Lexeo Therapeutics	$4.84 -2.4%	$4.65	$3.99 ▼ $10.99	$389.47M	1.46	1.07 million shs	676,569 shs
RCKT Rocket Pharmaceuticals	$3.47 +3.9%	$3.38	$2.53 ▼ $5.45	$366.65M	0.47	1.51 million shs	1.16 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	0.00%	0.00%	0.00%	0.00%	+63.91%
IPSC Century Therapeutics	-0.52%	-4.00%	-11.52%	-17.95%	+260.09%
LXEO Lexeo Therapeutics	-2.42%	+0.62%	+2.11%	-4.91%	+2.54%
RCKT Rocket Pharmaceuticals	+3.89%	-3.88%	-4.93%	+6.77%	+12.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$4.36	$4.30	$1.78 ▼ $5.75	$96.26M	0.87	452,470 shs	N/A
IPSC Century Therapeutics	$1.92 -0.5%	$2.19	$0.44 ▼ $3.04	$348.08M	1.57	656,371 shs	489,279 shs
LXEO Lexeo Therapeutics	$4.84 -2.4%	$4.65	$3.99 ▼ $10.99	$389.47M	1.46	1.07 million shs	676,569 shs
RCKT Rocket Pharmaceuticals	$3.47 +3.9%	$3.38	$2.53 ▼ $5.45	$366.65M	0.47	1.51 million shs	1.16 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	0.00%	0.00%	0.00%	0.00%	+63.91%
IPSC Century Therapeutics	-0.52%	-4.00%	-11.52%	-17.95%	+260.09%
LXEO Lexeo Therapeutics	-2.42%	+0.62%	+2.11%	-4.91%	+2.54%
RCKT Rocket Pharmaceuticals	+3.89%	-3.88%	-4.93%	+6.77%	+12.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	1.80	Reduce	$4.88	11.81% Upside
IPSC Century Therapeutics	2.43	Hold	$4.75	147.40% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$18.75	287.40% Upside
RCKT Rocket Pharmaceuticals	2.30	Hold	$8.57	147.02% Upside

Current Analyst Ratings Breakdown

Latest ADVM, RCKT, LXEO, and IPSC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	RCKT Rocket Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$16.00 ➝ $15.00
7/30/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/15/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/10/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/2/2026	IPSC Century Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/29/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/25/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/25/2026	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$12.00 ➝ $9.00

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	$3.40 per share	N/A
IPSC Century Therapeutics	$109.16M	3.17	$0.01 per share	145.11	$1.29 per share	1.49
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	$2.87 per share	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$3.36 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$8.58	N/A	N/A	N/A	N/A	-3,476.17%	-152.07%	N/A
IPSC Century Therapeutics	-$9.58M	-$1.14	N/A	N/A	N/A	N/A	-49.51%	-38.09%	N/A
LXEO Lexeo Therapeutics	-$99.96M	-$1.15	N/A	N/A	N/A	N/A	-41.85%	-38.03%	N/A
RCKT Rocket Pharmaceuticals	-$223.12M	-$0.17	N/A	N/A	N/A	N/A	-52.77%	-44.92%	N/A

Latest ADVM, RCKT, LXEO, and IPSC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	IPSC Century Therapeutics	-$0.11	-$0.17	-$0.06	-$0.17	$2.17 million	N/A
8/12/2026	Q2 2026	LXEO Lexeo Therapeutics	-$0.2852	-$0.30	-$0.0148	-$0.30	N/A	N/A
8/10/2026	Q2 2026	RCKT Rocket Pharmaceuticals	$0.86	$1.08	+$0.22	$1.08	$0.22 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	0.65	0.65
IPSC Century Therapeutics	N/A	8.28	10.25
LXEO Lexeo Therapeutics	N/A	13.89	14.16
RCKT Rocket Pharmaceuticals	0.05	9.24	6.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
IPSC Century Therapeutics	50.20%
LXEO Lexeo Therapeutics	60.67%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
IPSC Century Therapeutics	2.40%
LXEO Lexeo Therapeutics	2.00%
RCKT Rocket Pharmaceuticals	21.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	22.08 million	20.75 million	Optionable
IPSC Century Therapeutics	170	180.35 million	176.03 million	Optionable
LXEO Lexeo Therapeutics	58	78.52 million	76.95 million	Not Optionable
RCKT Rocket Pharmaceuticals	240	109.78 million	86.39 million	Optionable

ADVM, RCKT, LXEO, and IPSC Headlines

Recent News About These Companies

Rocket Pharmaceuticals (NASDAQ:RCKT) Insider Sells 4,701 Shares

August 14 at 7:52 AM | insidertrades.com

Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) Insider Sells $16,453.50 in Stock

August 13 at 5:21 PM | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) COO Christopher James Stevens Sells 36,658 Shares of Stock

August 13 at 5:21 PM | marketbeat.com

Wedbush Lowers Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $15.00

August 13 at 2:01 AM | americanbankingnews.com

Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus

August 11, 2026 | zacks.com

Wedbush Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price

August 11, 2026 | marketbeat.com

Rocket Pharmaceuticals: Q2 Earnings Snapshot

August 11, 2026 | aol.comA

Rocket Pharmaceuticals (NASDAQ:RCKT) Announces Quarterly Earnings Results, Beats Estimates By $0.22 EPS

August 10, 2026 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Lowered to "Sell" Rating by Wall Street Zen

August 9, 2026 | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Rating Lowered to Sell at Wall Street Zen

August 9, 2026 | marketbeat.com

Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial

August 3, 2026 | benzinga.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Raised to Hold at Wall Street Zen

August 1, 2026 | marketbeat.com

Rocket Pharmaceuticals (RCKT) to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Rocket Pharmaceuticals: Can The AAV9 Cardiovascular Pipeline Justify The Current Valuation?

July 29, 2026 | seekingalpha.com

Maverick Capital Ltd. Purchases 1,054,262 Shares of Rocket Pharmaceuticals, Inc. $RCKT

July 28, 2026 | marketbeat.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Recommendation of "Hold" from Analysts

July 27, 2026 | marketbeat.com

Wall Street Zen Downgrades Rocket Pharmaceuticals (NASDAQ:RCKT) to Sell

July 18, 2026 | marketbeat.com

Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone?

June 25, 2026 | insidermonkey.com

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

June 12, 2026 | rutlandherald.comR

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

June 12, 2026 | businesswire.com

Rocket Pharmaceuticals, Inc. (RCKT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 9, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADVM, RCKT, LXEO, and IPSC Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Century Therapeutics NASDAQ:IPSC

$1.92 -0.01 (-0.52%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.93 +0.01 (+0.47%)

As of 08/14/2026 07:34 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Lexeo Therapeutics NASDAQ:LXEO

$4.84 -0.12 (-2.42%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$4.95 +0.11 (+2.27%)

As of 08/14/2026 07:58 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.47 +0.13 (+3.89%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.45 -0.02 (-0.58%)

As of 08/14/2026 07:34 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADVM, RCKT, LXEO, and IPSC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADVM, RCKT, LXEO, and IPSC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADVM, RCKT, LXEO, and IPSC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADVM, RCKT, LXEO, and IPSC Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

Century Therapeutics NASDAQ:IPSC

Lexeo Therapeutics NASDAQ:LXEO

Rocket Pharmaceuticals NASDAQ:RCKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADVM, RCKT, LXEO, and IPSC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADVM, RCKT, LXEO, and IPSC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADVM, RCKT, LXEO, and IPSC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADVM, RCKT, LXEO, and IPSC Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

Century Therapeutics NASDAQ:IPSC

Lexeo Therapeutics NASDAQ:LXEO

Rocket Pharmaceuticals NASDAQ:RCKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools